Drugs / QT-219CX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07586267 | May 2026 → May 2029 expected | IgA glomerulonephritis, anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic multidrug-resistant nephrotic syndrome, systemic lupus erythematosus +1 | The Children's Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QT-219CX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07586267 ↗ |
| Action | Deplete | “the therapy aims to achieve deep and extensive depletion of pathogenic immune cells” NCT07586267 ↗ |
| Modality | Cell therapy | “universal allogeneic chimeric antigen receptor T-cell (CAR-T) product” NCT07586267 ↗ |
| Route | Intravenous | “a single intravenous infusion of QT-219CX” NCT07586267 ↗ |
| Target | BCMA | “targeting both CD19 and BCMA” NCT07586267 ↗ |
| Target | CD19 | “targeting both CD19 and BCMA” NCT07586267 ↗ |